Endo International — Barclays Healthcare Conference 2016
18 slides from Endo International's conference presentation, Mar 17, 2016

Slide 1: Endo International plc Barclays Healthcare Conference
Endo International plc Barclays Healthcare Conference March 17, 2016 ©2016 Endo Pharmaceuticals Inc. All rights reserved. Exhibit 99.1

Slide 2: Forward Looking Statements; Non-GAAP Financial Measures
Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. Statements including words such as “believes,” “expects,” “anticipates,” “inte

Slide 3: Endo's Execution & Growth in 2016: Key Priorities for the Year
Strong commercial launch of BELBUCA™ Continued growth for XIAFLEX® in approved indications Generics integration and continued growth Advancement of XIAFLEX® R&D pipeline Continued Par pipeline momentum and productivity Continued de-levering Underlying growth in emerging markets Endo’s Execution & Gr

Slide 4: U.S. Branded: BELBUCA Treatment Pathways & 2016 Expectations
U.S. Branded: BELBUCA™ Treatment Pathways & 2016 Expectations Schedule III product – offers proven efficacy and safety of buprenorphine with buccal film technology May help reduce the potential for misuse and potentially lessen the incidence of certain side effects 2016 revenue cadence expectations

Slide 5: U.S. Branded: Opioids & the CDC Guidelines
U.S. Branded: Opioids & the CDC Guidelines ©2016 Endo Pharmaceuticals Inc. All rights reserved. Committed to the responsible prescribing and use of opioid products CDC guidelines are voluntary and exclude cancer and palliative care; physicians must be able to treat the unique needs of each individua

Slide 6: U.S. Branded: XIAFLEX Growth Initiatives
U.S. Branded: XIAFLEX® Growth Initiatives XIAFLEX® growth initiatives underway campaign More than tripling speaker program events in 2016; engagement and attendance have been very strong Enhanced physician targeting Modest price increase effective March 1, 2016 with volume-based discount program No

Slide 7: U.S. Branded: XIAFLEX 2016 Cadence & Expectations
U.S. Branded: XIAFLEX® 2016 Cadence & Expectations Project double-digit revenue growth for 2016 vs. 2015 Seasonal Q1 2016 step-down expected Patient trends & deductibles Normal inventory fluctuations Expect 2H 2015 and 1H 2016 activities to drive growth in 2H 2016 Leading performance indicators tren

Slide 8: U.S. Generics: 2016 Projected Growth Drivers
U.S. Generics: 2016 Projected Growth Drivers ©2016 Endo Pharmaceuticals Inc. All rights reserved. Base business erosion continuing in Q1 Consortium bids submitted; impact only known in Q2 Select product events could impact segment growth rates E.g.: Alternative dosage product awaiting FDA action

Slide 9: U.S. Generics: 2016 Product Launch Expectations
U.S. Generics: 2016 Product Launch Expectations ~30 product launches expected 4 First-to-File products 2 Alternative dosage products 9 Sterile injectable products ©2016 Endo Pharmaceuticals Inc. All rights reserved. H1 2016 H2 2016 # of Competitors 0 3+ 2 1 U.S. Generics: Anticipated 2016 Product La

Slide 10: International: 2016 Expectations
International: 2016 Expectations Reported revenue expected to decline 2016 vs. 2015 due to: Stronger U.S. dollar - current exchange rates assumed for foreign currency conversion Product divestitures and LOEs Q1 2016 expectations: Seasonality and historical stocking fluctuations Double-digit underlyi

Slide 11: Endo: Tax Rate Trends
Endo: Tax Rate Trends ©2016 Endo Pharmaceuticals Inc. All rights reserved. 2014 2015 2016 Cash Tax Rate -10% -2% Negative* Adjusted Effective Tax Rate (ETR) Provided by company in adjusted financial results & guidance 22% 4% 9% - 11% Adjusted ETR approach: Apply statutory tax rates to adjusted pre-t

Slide 12: 2016: Q1 Considerations
2016: Q1 Considerations U.S. Branded Project a step-down in Q1 revenues vs. Q4 2015 due to expected seasonality Early investment in the early ramp of BELBUCA™ Early investment in XIAFLEX® marketing and DTC U.S. Generics Erosion in Generics Base business continuing in Q1 Q1 2015 included exclusivity

Slide 13: 2016 Financial Guidance (Continuing Operations)
2016 Financial Guidance (Continuing Operations*) ©2016 Endo Pharmaceuticals Inc. All rights reserved. Measure FY 2016 Guidance Q1 2016 Latest View Implied Revenues $4.32 – $4.52B ~$928M – $972M Adjusted Gross Margin 63% - 65% Adjusted Operating Expense to Revenue Ratio 19.5% - 20% Adjusted Interest

Slide 14: Endo's Execution & Growth in 2016: Key Priorities for the Year
Strong commercial launch of BELBUCA™ Continued growth for XIAFLEX® in approved indications Generics integration and continued growth Advancement of XIAFLEX® R&D pipeline Continued Par pipeline momentum and productivity Continued de-levering Underlying growth in emerging markets Endo’s Execution & Gr

Slide 15: Q&A
Q&A ©2016 Endo Pharmaceuticals Inc. All rights reserved.

Slide 16: Appendix
Appendix ©2016 Endo Pharmaceuticals Inc. All rights reserved.

Slide 17: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures ©2016 Endo Pharmaceuticals Inc. All rights reserved. Reconciliation of Projected GAAP Diluted Earnings Per Share from Continuing Operations to Adjusted Diluted Earnings Per Share from Continuing Operations Guidance for 2016 Year Ending December 31, 2016 Lower End

Slide 18: Endo International plc Barclays Healthcare Conference
Endo International plc Barclays Healthcare Conference March 17, 2016 ©2016 Endo Pharmaceuticals Inc. All rights reserved.
Source: SEC EDGAR · 8-K filed Mar 17, 2016
More decks from Endo International PLC
Corporate Update (November 2023)18 slides · Nov 6, 2023
Corporate Update (February 2023)19 slides · Feb 14, 2023
Corporate Update (December 2022)6 slides · Dec 6, 2022
Investor Presentation (August 2022)72 slides · Aug 17, 2022
Q4 2021 Earnings Presentation21 slides · Feb 28, 2022
J.P. Morgan Healthcare Conference 202213 slides · Jan 11, 2022